ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 16.67 percent decrease over losses of $(0.90) per share from the same period last year.